Document is current
Any future updates will be listed below
-
Authors
Martin, Beth K. https://orcid.org/0000-0002-9661-014X
Qiu, Chengxiang
Nichols, Eva
Phung, Melissa
Green-Gladden, Rula https://orcid.org/0000-0001-5779-8525
Srivatsan, Sanjay https://orcid.org/0000-0001-7282-0487
Blecher-Gonen, Ronnie
Beliveau, Brian J. https://orcid.org/0000-0003-1314-3118
Trapnell, Cole https://orcid.org/0000-0002-8105-4347
Cao, Junyue
Shendure, Jay https://orcid.org/0000-0002-1516-1865
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01HG010632, UM1HG011586, T32HG000035, UM1HG011586, R01HG010632)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM137916)
- License Information
-
More Information
Article History
Received: 2 February 2022
Accepted: 30 June 2022
First Online: 19 October 2022
Competing interests
: J.S. is a scientific advisory board member, consultant and/or cofounder of Cajal Neuroscience, Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Phase Genomics, Adaptive Biotechnologies and Scale Biosciences. C.T. is a founder of Scale Biosciences. All other authors have no competing interests.
